Study of NURTEC ODT 75 mg after market release in Korea
Part of Brain & nervous system, Pain clinical trials.
This study looks at patients who have already taken NURTEC ODT 75 mg as prescribed. It aims to gather more information about the medicine after it is available on the market in Korea.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years old or older.
- You have taken NURTEC ODT 75 mg exactly as your doctor prescribed.
- You sign a consent form agreeing to be in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental tablet, BR005-036C, to see if it safely and effectively stops migraine attacks in adults. If you have migraines, this could offer a new option for fast relief when a headache starts.
This study tests if the medicine rimegepant is safe for people with migraine. You may be able to join if you have had migraine for at least a year, have 4–14 migraine days per month, and have not had good results with other migraine medicines called triptans.
This trial tests two fast-dissolving migraine medicines, Nurtec ODT and Maxalt MLT-ODT, in adults coming to the emergency room with a migraine. The goal is to see which one works better and faster for pain relief.
This study tests a medicine called rimegepant to see if it helps prevent migraines. If you have migraine at least 4 days per month, this might be for you.
This study tests whether taking an additional dose of rimegepant (a migraine medicine you may already use) is safe and helpful for adults with migraine. Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist—a type of medicine that blocks a protein involved in migraine pain.
This Phase 3 study checks the long-term safety of rimegepant, a migraine treatment, in children and teens. You might join if your child has had migraine for at least 6 months and still gets a certain number of moderate-to-severe migraine attacks.
Hear when a new Migraine With or Without Aura trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.